In SMA-560 glioma-bearing mice, the tumor size at an early stage was similar across the different treatment groups, except for a trend in volume reduction for animals treated with GITRL-Fc and a TGF-β receptor inhibitor (Fig. 5A). This evidence concerns the gene TNFSF18 and central nervous system cancer.